Tenderwize
Zurück zur Suche

Ranibizumab

AOK Bremen/Bremerhaven·Bremen, Germany·Deadline Nov 04, 2027 · 436 days left·Open·Supplies
Registrieren zum SpeichernOpen documents
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open-House-Verträge 2025-4

52/100

Opportunity Score

Needs reviewMedium complexity
SuppliesOpen
Warum diese Bewertung?

Chance

52 / 100

Komplexität

58 / 100

Risikofaktoren

The structured data, lot description, and XML notice text contain different contract end dates and start/end periods.

Electronic submission is marked as not allowed, while the notice also refers to email and downloadable participation do...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Open-house supply contracts for pharmaceutical products / active substances under § 130a Abs. 8 SGB V.
  • Ranibizumab lot: contract access for the named active substance, excluding medicines on the BfArM children's medicines list.
Vollständige Zusammenfassung anzeigen

Open-house supply arrangement for pharmaceutical products in Germany, led by AOK Bremen/Bremerhaven. The notice states that interested pharmaceutical companies may join on equal terms, with no exclusivity and no individual negotiations. One lot is identified for Ranibizumab (ATC S01LA04). The notice contains a major inconsistency: the structured data says the contract runs until 31.12.2027, while the XML notice for the lot states 31.12.2025 and the XML notice text also mentions 31.05.2027 / 01.06.2025. Because of this, deadline and duration should be verified before bidding.

Risiken

The structured data, lot description, and XML notice text contain different contract end dates and start/end periods.

Electronic submission is marked as not allowed, while the notice also refers to email and downloadable participation do...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Only pharmaceutical undertakings within the meaning of § 4 Abs. 18 AMG may conclude the rebate contract for the offered medicines.

Certifications

  • For bidders established outside Germany, proof of registration in a comparable register from the home country must be provided in a certified German translation.

Administrative

  • The buyer requests self-declarations on reliability and delivery capability, and a self-declaration on Russia sanctions.

Auftraggeber

Ort

Bremen, DEU

Website

www.aok.de

Kennung

DE114397726

Tätigkeit

Health

Lose (1)

LOT-0001

Ranibizumab

Supply/open-house contract for Ranibizumab (ATC S01LA04) under § 130a Abs. 8 SGB V. The lot excludes medicines on the BfArM list under § 35 Abs. 5a SGB V (children's medicines). Interested pharmaceutical companies or groups of companies may join under identical conditions; no exclusivity and no individual negotiations are stated. The lot is based on notice text and structured data.

SuppliesEU fundedElectronic submission

Ort

Germany

Kategorie

Pharmaceutical products

Frist

Expired Dec 31, 2025

Vergabedetails

Veröffentlichungsdatum
04 Nov 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
730881-2025

Dokumente (1)

Vergabedokument 1

Ähnliche Ausschreibungen

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3